Contineum Therapeutics develops small molecule drugs for lung fibrosis, chronic pain, depression and multiple sclerosis. It last closed at $8.68 on Nov 20, down 3.98% on the day. The next earnings report for CTNM is expected around Thu, Mar 4, 2027, after the close. For the quarter ended Sep 2026, CTNM reported EPS of -$0.49. Over its last 8 reports the stock moved an average of 3.1% the session after earnings. Over the last 12 months CTNM insiders bought $0 of stock on the open market and sold $1.9M, according to SEC Form 4 filings.
AI Auto Pilots
Is CTNM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CTNM.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on CTNMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
CTNM · as of the Nov 20 close · updated each morning
Downtrend
The stock is 9% below its 20 day and 23% below its 50 day average. It is 53% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the swing low (Nov 6) at $8.59, and the nearest resistance the Pivot at $8.76.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 9.1%/day
Key levels
$17.7952 week high+105.0%
$13.27200 day average+52.9%
$13.00100 day average+49.8%
$10.6650 day average+22.8%
$9.4920 day average+9.3%
$9.03Pivot R1+4.0%
$8.79Swing high (Oct 21)+1.3%
$8.76Pivot+0.9%
$8.68Last close
$8.59Swing low (Nov 6)−1.0%
$8.42Pivot S1−3.0%
$6.7252 week low−22.6%
Indicators
RSI (14)
38.98
Weak, oversold below 30
Neutral
MACD
-0.32
Above its signal line
Bullish
Stochastic
18.3
Near the bottom of its range
Oversold
ADX (14)
21.1
Weak trend
Williams %R
-92.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-109.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−8.8%
Change over 10 sessions
Bearish
ATR (14)
$0.79
Typical daily range, 9.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityHigh, 25.6%/day
Key levels
$17.7952 week high+105.0%
$13.27200 day average+52.9%
$13.00100 day average+49.8%
$10.6650 day average+22.8%
$9.4920 day average+9.3%
$9.03Pivot R1+4.0%
$8.79Swing high (Oct 21)+1.3%
$8.76Pivot+0.9%
$8.68Last close
$8.59Swing low (Nov 6)−1.0%
$8.42Pivot S1−3.0%
$6.7252 week low−22.6%
Indicators
RSI (14)
38.06
Weak, oversold below 30
Neutral
MACD
-1.23
Below its signal line
Bearish
Stochastic
23.8
Middle of its range
Neutral
ADX (14)
25.9
Trending down
Williams %R
-82.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-106.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−41.4%
Change over 10 sessions
Bearish
ATR (14)
$2.23
Typical daily range, 25.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for CTNM
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CTNM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for CTNMHow many large options trades hit CTNM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in CTNM in the last 90 days.
From SEC Form 4 filings by CTNM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CTNM is in one of them and how their past CTNM trades turned out.
Contineum Therapeutics is a San Diego, California company developing small molecule drugs for neuroscience and immunology conditions. Its lead candidate, PIPE-791, is being developed as a pill taken once a day for idiopathic pulmonary fibrosis and is also being studied for chronic pain. A second candidate, PIPE-307, is being developed for depression and multiple sclerosis in partnership with Johnson & Johnson. The company's drugs are intended for patients with these conditions, and none are approved for sale yet.